All sponsors

Rhythm Pharmaceuticals, Inc. $RYTM

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%

Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.4 months). See all sponsors →

Open Rhythm Pharmaceuticals, Inc. on the live radar map → 📅 $RYTM readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Setmelanotide
NCT05774756
P3Active, not recruitingHypothalamic Obesity1432025-03-18
Setmelanotide
NCT06772597
P2Active, not recruitingPrader-Willi Syndrome; Obesity182026-11-03 (+9 mo)
Setmelanotide
NCT06760546
P3RecruitingHypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form392027-03-13 (+1 mo)
Part C: RM-718
NCT06239116
P1/2Active, not recruitingHypothalamic Obesity; Prader-Willi Syndrome1112027-05-07 (+22 mo)
Bivamelagon
NCT07156578
P2Enrolling by invitationHypothalamic Obesity252028-04-15